USRM (US Stem Cell) Change In Receivables: $-0.00 Mil (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Change In Receivables?

US Stem Cell USRM 12 Change In Receivables is $-0.00 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's change in receivables for the quarter that ended in Dec. 2022 was $-0.00 Mil. It means US Stem Cell's Accounts Receivable increased by $0.00 Mil from Sep. 2022 to Dec. 2022 .

US Stem Cell's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.00 Mil. It means US Stem Cell's Accounts Receivable increased by $0.00 Mil from Dec. 2021 to Dec. 2022 .

US Stem Cell's Accounts Receivable for the quarter that ended in Dec. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. US Stem Cell's Days Sales Outstanding for the three months ended in Dec. 2022 was 18.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. US Stem Cell's liquidation value for the three months ended in Dec. 2022 was $-14.80 Mil.

US Stem Cell  (OTCPK:USRM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

US Stem Cell's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.004/0.02*91
=18.25

2. In Ben Graham's calculation of liquidation value, US Stem Cell's accounts receivable are only considered to be worth 75% of book value:

US Stem Cell's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.005-14.813+0.75 * 0.004+0.5 * 0.001
=-14.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Change In Receivables Related Terms

US Stem Cell Change In Receivables Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Change In Receivables Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.08 -0.01 -0.04 -0.00

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.01 -0.00
USRM
12GF Score
US Stem Cell Inc USRM
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.00 Mil mean?
US Stem Cell (USRM) has a Change In Receivables of $-0.00 Mil as of Dec. 2022. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for US Stem Cell and its competitors.
Is US Stem Cell's Change In Receivables too high?
US Stem Cell's current Change In Receivables is $-0.00 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Change In Receivables compare to NOVNQ and RGRX?
US Stem Cell's Change In Receivables of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for US Stem Cell and its competitors. US Stem Cell's current Change In Receivables is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Change In Receivables of $-0.00 Mil. The current Change In Receivables is $-0.00 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For US Stem Cell (USRM), the current Change In Receivables is $-0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price